Search
forLearn
5 / 801 resultslearn Hydroxypropyltrimonium Chloride
learn Carpronium chloride hydrate
learn Hydrocortisone Valerate
learn Hydroxychloroquine sulphate
Research
5 / 1000+ results
research Non-competitive androgen receptor inhibition in vitro and in vivo
Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.
research Dextran hydrogel scaffolds enhance angiogenic responses and promote complete skin regeneration during burn wound healing
Dextran hydrogels improve burn wound healing and skin regeneration.
research Sex Hormones and Frailty in Older Men: The Osteoporotic Fractures in Men (MrOS) Study
Older men with lower levels of available testosterone are more likely to be frail.
research Endocrine evaluation of hirsutism
Women with excessive male-pattern hair growth should get a full hormone check-up to find and treat any underlying issues, considering both medical and emotional aspects.
research Endocrine evaluation of hirsutism
Hirsutism, excessive hair growth in women, is often caused by PCOS and can be managed with medication and personalized treatment plans.
Community Join
5 / 1000+ resultscommunity Minokem-N cotains hydrocortisone?
Minokem-N's composition is unclear, with concerns about unlisted hydrocortisone. Users discuss alternatives like AloATM, which lacks soothing agents, and the challenges of verifying ingredients.
community Hydrocortisone helps with itch
Hydrocortisone helps relieve scalp itchiness, possibly caused by minoxidil. Users discuss its effectiveness for managing this side effect.
community Hydrophobic Finasteride. Why don’t we have it?
The conversation discusses the potential benefits of creating a hydrophobic version of finasteride to reduce systemic side effects while maintaining scalp health. It compares this idea to fluridil, which is designed to be hydrophobic and has less systemic absorption.
community Hope Medicine's HMI-115 could be out in 2027 per Company Founder
Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.
community HMI-115: What We Know So Far. HMI-115 (also known as BAY1158061) is a new pharmaceutical drug developed by a biopharmaceutical company called Bioinvent and licensed by Bayer
HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.